It’s never been as clear to identify node-positive patients who can safely be spared chemotherapy1,2
Node Positive Patients
Additional RxPONDER data to be presented at SABCS 2021:

Oral Presentation
Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with Recurrence Score® (RS) < or = 25 randomized to endocrine therapy (ET) +/-chemotherapy (CT): SWOG s1007 (RxPONDER)
GS2-07 | Kalinsky

RxPONDER builds on data from SWOG-8814 that established chemotherapy benefit for node positive (1-3 nodes) patients with Recurrence Score® results 26-1001,2,3


RxPONDER SWOG-8814 Chart


CT benefit expressed in percentage points based on probability of distant recurrence with/without CT at 5 years.
No CT benefit is considered for an absolute benefit <1%.
[*] Benefit of chemotherapy for premenopausal N1 patients with Recurrence Score (RS) results 26-100 has not been formally assessed in a randomized study. The benefit derived from chemotherapy was significant for RS results 0-13 and 14-25 in the RxPONDER study and it is inferred to be substantial for patients with RS result 26-100.

Guide your node-positive patients to the right treatment decisions, with confidence.

Safely spare postmenopausal patients chemotherapy with confidence1

Postmenopausal women with 1-3 positive nodes and Recurrence Score (RS) results 0-25 can safely forgo chemotherapy regardless of tumor size, grade or number of lymph nodes involved.1
RxPONDER Post-Menopausal Chart

Determine chemotherapy options for N1 premenopausal patients with precision3

Premenopausal women with 1-3 positive nodes and Recurrence Score results 0-25 have a modest chemotherapy benefit.4
RxPONDER Pre-Menopausal Chart

RxPONDER was prospectively designed to refine adjuvant treatment decisions in N1 breast cancer patients11


RxPONDER N1 Chart



Challenging Node-positive Case Studies Webinar

View an exchange between Drs. Jeremy Force and Christy Russell where they discuss challenging node-positive breast cancer patient case studies. Learn how physicians can use the Breast Recurrence Score® test and the recently presented data from the RxPONDER trial to inform chemotherapy treatment decisions for HR-positive, HER2-negative breast cancer patients.

Presenters:

Jeremy Force, DO
Assistant Professor
Duke University School of Medicine
Christy Russell, MD
Vice President, US Medical Affairs
Exact Sciences

REFERENCES

  1. Kalinsky et al. Oral Presentation [GS3-00]. SABCS. 2020.
  2. Albain K et al. Lancet Oncol. 2010.
  3. National Cancer Institute. 2021.
  4. Sparano J et al. N Engl J Med. 2018.

Making cancer care smarter.™